Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
J Alzheimers Dis ; 93(1): 321-332, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37005886

RESUMEN

BACKGROUND: Verbal fluency tasks are frequently used for neuropsychological assessment in clinical practice and research. It consists of two tasks namely category and letter fluency tests. OBJECTIVE: To determine normative values in category (animals, vegetables, fruits) and letter fluency [Mim () "M", Alif () "A", Baa () "B"] tasks in Arabic language in 60 s. METHODS: This study was a cross-sectional national survey and included 859 community-dwelling, cognitively intact Lebanese residents aged ≥55 years. Norms were presented according to age (55-64 years, 65-74 years, ≥75 years), sex and level of education (illiterate, no diploma, primary certificate, baccalaureate or higher). RESULTS: Level of education had the most significant positive effect on verbal fluency tasks performance amongst Lebanese older adults. The negative effect of older age was more prominent in the category fluency task compared to the letter fluency task. Women outperformed men in vegetables and fruits categories. CONCLUSION: This study provides clinicians with normative scores of category and letter fluency tests, which can be used for neuropsychological assessment of older Lebanese patients being evaluated for cognitive disorders.


Asunto(s)
Disfunción Cognitiva , Lenguaje , Humanos , Estudios Transversales , Pruebas Neuropsicológicas , Escolaridad , Conducta Verbal
2.
J Int Neuropsychol Soc ; 29(3): 316-323, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-35504862

RESUMEN

OBJECTIVES: In the absence of a simple validated instrument to screen for cognitive impairment among illiterate Lebanese older adults, the aims of this study were to validate an Arabic version of the Test of Nine Images (A-TNI93) adapted by the Working Group on Dementia at Saint Joseph University: Groupe de Travail sur les Démences de l'Univesité Saint Joseph (GTD-USJ) for illiterate older Lebanese and to establish normative data. METHOD: A national population-based sample of 332 community-dwelling illiterate Lebanese aged 55 years and older was administered the A-TNI93 (GTD-USJ) scoring free and overall recall. The sample is part of a larger national sample (1342 participants) used to validate an Arabic version of the Mini-Mental State Examination already reported. Reproducibility, sensitivity, specificity, and area under the curve of the A-TNI93 (GTD-USJ) scoring to detect cognitive impairment according to Clinical Dementia Rating (CDR) as the gold standard were measured. Normative data were established among 188 cognitively normal participants. RESULTS: A threshold score of six on free recall (FR) provided a sensitivity of 66.7% and a specificity of 90.5%. The area under the curve was 0.93. By taking either scores, that is, a FR ≤ 6 or a total recall ≤ 8, the A-TNI93 (GTD-USJ) slightly improved dementia case detection with a sensitivity of 70.8% and a specificity of 88%. Normative data illustrate the distribution of cognitive performance among illiterate older adults. CONCLUSIONS: Compared to the CDR requiring physician's competence, the A-TNI93 (GTD-USJ) is a valid Arabic adaptation to screen for cognitive impairment among illiterate Lebanese older adults.


Asunto(s)
Disfunción Cognitiva , Demencia , Humanos , Anciano , Reproducibilidad de los Resultados , Disfunción Cognitiva/diagnóstico , Pruebas de Estado Mental y Demencia , Alfabetización , Demencia/diagnóstico , Demencia/psicología , Pruebas Neuropsicológicas
3.
Clin Geriatr Med ; 38(1): 119-131, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34794696

RESUMEN

Nicotine is one of the most abused substances worldwide. Just as in adolescence and adulthood, tobacco use is also problematic in the elderly. Older people are more vulnerable to smoking consequences because of the additive effects of smoke. Cardiovascular diseases are the most common health problems associated with smoking; however, other systems are also affected, including the respiratory, nervous, integumentary, and many other systems. Smoking cessation is a difficult task especially in the elderly; therefore, physicians should encourage older patients to quit with every patient-physician encounter by offering counseling and replacement therapy.


Asunto(s)
Cese del Hábito de Fumar , Tabaquismo , Adulto , Anciano , Humanos , Nicotina/efectos adversos , Fumar , Tabaquismo/epidemiología , Tabaquismo/terapia
4.
J Alzheimers Dis ; 71(2): 525-540, 2019 08 12.
Artículo en Inglés | MEDLINE | ID: mdl-31424409

RESUMEN

BACKGROUND: The Mini-Mental State Examination (MMSE) has not been validated in the Lebanese population and no normative data exist at the national level. OBJECTIVE: To evaluate the reliability and validity of an Arabic version of MMSE developed by the "Groupe de Travail sur les Démences de l'Université Saint Joseph" (A-MMSE(GTD-USJ)) and to provide normative data by gender, age, and education in adults over 55. METHODS: Study design: national cross-sectional survey. STUDY POPULATION: 1,010 literate community-dwelling Lebanese residents aged 55 and above. OUTCOMES: reproducibility, internal consistency, sensitivity, specificity, predictive values, and area under the curve of the A-MMSE(GTD-USJ) for the detection of cognitive impairment using the Clinical Dementia Rating (CDR) as the gold standard. Normative data were established from 720 healthy adults. A-MMSE(GTD-USJ) scores corresponding to the 5th, 10th, 15th, and 50th percentiles were identified according to gender, age, and education. RESULTS: Intra-rater and inter-rater test-retest score correlations were 0.89 and 0.72, respectively. Cronbach alpha coefficient for internal consistency of the A-MMSE(GTD-USJ) was 0.71. A threshold value of 23 provided a sensitivity of 80% and a specificity of 89.4%. The area under the curve was 0.92. A-MMSE(GTD-USJ) scores increased with education and decreased with age. Women had significantly lower scores than men. Normative data for A-MMSE(GTD-USJ) stratified by gender, age, and education were generated. CONCLUSION: In reference to the CDR, the A-MMSE(GTD-USJ) is a valid tool to assess cognitive status among Lebanese subjects aged 55 and above. Normative data will help clinicians in detecting cognitive impairment in this population.


Asunto(s)
Árabes/psicología , Disfunción Cognitiva/diagnóstico , Pruebas de Estado Mental y Demencia , Anciano , Disfunción Cognitiva/psicología , Estudios Transversales , Demencia/diagnóstico , Demencia/psicología , Femenino , Humanos , Líbano , Masculino , Pruebas de Estado Mental y Demencia/normas , Persona de Mediana Edad , Valores de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
5.
J Med Liban ; 64(2): 65-71, 2016 08.
Artículo en Inglés, Francés | MEDLINE | ID: mdl-30452142

RESUMEN

BACKGROUND: Medical conditions and depen- dency levels of the elderly in the Lebanese long-term care institutions have not been described. This may undermine care commissioning and development to institutionalized elderly. Data to inform policy and practice are needed. OBJECTIVE: To identify clinical diagnoses and dependency levels among elderly residents in long-term care institutions in Lebanon. METHODS: Cross-sectional survey of long-term care institutions throughout Lebanon as identified by the Mihistry of Social Affairs. RESULTS: Thirty-one out of 42 long- term care institutions have been included in this survey. Among them, 1371 elderly subjects were included in the analysis; 75.6% were over the age of 75, and female repre- sented 67%. Medical morbidities and associated disabilities have driven admission in 70.5% of residents; 45.6% of resi- dents reported dernentia, stroke or other neurodegenerativb disease. Overall, 60% of residents required locomotor assis- tance. CONCLUSIONS: Elderly residents in long-term carb institutions are predominantly females, with mental and/or locomotor disabilities resulting fror neurological and ar- thritic conditions. Targeting healthcare for such health condi- tions remains a challenge for the institutions.


Asunto(s)
Estado de Salud , Casas de Salud , Anciano , Anciano de 80 o más Años , Estudios Transversales , Demencia/epidemiología , Depresión/epidemiología , Femenino , Anciano Frágil , Evaluación Geriátrica , Humanos , Líbano/epidemiología , Masculino , Enfermedades Musculoesqueléticas/epidemiología , Enfermedades del Sistema Nervioso/epidemiología , Incontinencia Urinaria/epidemiología
6.
Clin Interv Aging ; 10: 1779-87, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26622172

RESUMEN

PURPOSE: Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer's disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer's disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer's disease. PATIENTS AND METHODS: RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer's disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24. RESULTS: A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers' preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transdermal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001). CONCLUSION: Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Inhibidores de la Colinesterasa/uso terapéutico , Cumplimiento de la Medicación/estadística & datos numéricos , Administración Cutánea , Administración Oral , Anciano , Anciano de 80 o más Años , Asia , Actitud del Personal de Salud , Cuidadores/psicología , Inhibidores de la Colinesterasa/administración & dosificación , Inhibidores de la Colinesterasa/efectos adversos , Donepezilo , Femenino , Galantamina/uso terapéutico , Humanos , Indanos/uso terapéutico , Masculino , Memantina/uso terapéutico , Medio Oriente , Prioridad del Paciente , Médicos , Piperidinas/uso terapéutico , Estudios Prospectivos , Rivastigmina/uso terapéutico
7.
J Geriatr Psychiatry Neurol ; 27(4): 282-90, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24771602

RESUMEN

OBJECTIVES: In the North Africa and Middle East region, the illiteracy rates among older people are high, posing a great challenge to cognitive assessment. Validated diagnostic instruments for dementia in Arabic are lacking, hampering the development of dementia research in the region. The study aimed at validating the Arabic version of the 10/66 Dementia Research Group (DRG) diagnostic assessment for dementia to determine whether it is suitable for case ascertainment in epidemiological research. METHODS: A total of 244 participants older than 65 years were included, 100 with normal cognition and 144 with mild to moderate dementia. Dementia was diagnosed by clinicians according to Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria. Depression was diagnosed using the Geriatric Mental State. Trained interviewers blind to the cognitive status of the participants administered the 10/66 DRG diagnostic assessment to the participants and interviewed the caregivers. The discriminatory ability of the 10/66 DRG assessment and its subcomponents were evaluated against the clinical diagnoses. RESULTS: Half of the participants had no formal education and 49% of them were depressed. The 10/66 DRG diagnostic assessment showed excellent sensitivity (92.0%), specificity (95.1%), positive predictive value (PPV, 92.9%), and low false-positive rates among controls with no formal education (8.1%) and depression (5.6%). Each subcomponent of the 10/66 DRG diagnostic assessment independently predicted dementia diagnosis. The predictive ability of the 10/66 DRG assessment was superior to that of its subcomponents. CONCLUSION: The 10/66 DRG diagnostic assessment for dementia is well suited for case ascertainment in epidemiological studies among Arabic-speaking older population with high prevalence of illiteracy.


Asunto(s)
Demencia/diagnóstico , Depresión/diagnóstico , Lenguaje , Encuestas y Cuestionarios , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Demencia/psicología , Depresión/psicología , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Escolaridad , Femenino , Humanos , Líbano , Masculino , Prevalencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Traducción
9.
Med Clin North Am ; 95(3): 507-23, x, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21549875

RESUMEN

Late-onset hypogonadism is a clinical and biological syndrome associated with advancing age and characterized by typical symptoms and a deficiency in serum testosterone levels. It is a common condition but often underdiagnosed and undertreated. The main symptoms of hypogonadism are reduced libido/erectile dysfunction, reduced muscle mass and strength, increased adiposity, osteoporosis/low bone mass, depressed mood, and fatigue. Testosterone replacement therapy is only warranted in the presence of both clinical symptoms suggesting hormone deficiency and decreased hormone levels. It improves libido and sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, cognition, quality of life, and cardiovascular disease.


Asunto(s)
Evaluación Geriátrica/métodos , Hormonas Esteroides Gonadales/uso terapéutico , Hipogonadismo/diagnóstico , Hipogonadismo/tratamiento farmacológico , Salud del Hombre , Testosterona/uso terapéutico , Edad de Inicio , Anciano , Anciano de 80 o más Años , Envejecimiento/efectos de los fármacos , Disfunción Eréctil/etiología , Disfunción Eréctil/prevención & control , Estado de Salud , Humanos , Hipogonadismo/complicaciones , Libido/efectos de los fármacos , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/tratamiento farmacológico , Osteoporosis/complicaciones , Osteoporosis/tratamiento farmacológico
10.
J Gerontol A Biol Sci Med Sci ; 65(12): 1387-92, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20679073

RESUMEN

BACKGROUND: Patients with delirium, compared with those without, are at increased risk for loss of function, longer hospital stays, and increased mortality. We studied the effect that an Acute Care of the Elderly Unit, which includes a delirium room, has on patients with delirium. METHODS: Retrospective observational study. Charts of 148 patients (≥65 years) admitted to an Acute Care of the Elderly Unit with a delirium room during a 4-month period were reviewed. Delirium on admission (prevalence) was based on physician-performed Confusion Assessment Method; delirium during hospital stay (incidence) was based on nurse-performed Confusion Assessment Method. Patients with delirium were compared with those without delirium regarding change in function between admission and discharge (activities of daily living), hospital length of stay, and mortality. RESULTS: The prevalence of delirium was 16.2% (24/148), and the incidence was 16.1% (20/124). There were no significant differences between delirious and non-delirious patients in demographics or comorbidity scores. A significant interaction effect (p < .001) indicated improved activities of daily living (mean ± SD; scale 0-12) between admission and discharge among delirious patients (4.1 ± 4.6 and 6.1 ± 3.9) compared with non-delirious patients (7.4 ± 4.7 and 6.9 ± 4.5). There were no differences between delirious and non-delirious patients with reference to mean length of stay (6.4 ± 3.1 vs 5.9 ± 3.6 days, respectively; p = .461) and mortality (2 [4.5%] versus 2 [1.9%], respectively; p = .582). CONCLUSIONS: Although this study sample was small, the results suggest that an Acute Care of the Elderly Unit with a delirium room may improve function among delirious patients and may equalize other outcomes compared with non-delirious patients.


Asunto(s)
Delirio/fisiopatología , Delirio/terapia , Geriatría/métodos , Pacientes Internos , Tiempo de Internación , Grupo de Atención al Paciente , Actividades Cotidianas , Anciano , Anciano de 80 o más Años , Delirio/epidemiología , Delirio/mortalidad , Femenino , Humanos , Incidencia , Masculino , Análisis Multivariante , Prevalencia , Estudios Retrospectivos , Resultado del Tratamiento
11.
Expert Opin Pharmacother ; 11(10): 1765-71, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20540654

RESUMEN

IMPORTANCE OF THE FIELD: Alzheimer's disease is a progressive, degenerative brain disease. As the disease progresses, patients and caregivers face increasing problems with medication adherence. Given its relentlessly progressive nature, newer and more effective therapies for Alzheimer's disease are needed. Memantine 10 mg twice daily is the FDA-approved regimen for the treatment of moderate to severe Alzheimer's disease. AREAS COVERED IN THIS REVIEW: The goal of this article is to review the once-daily memantine ER 28 mg formulation for the treatment of Alzheimer's disease, which, by simplifying the dosage regimen, decreases the problems of medication adherence. A new extended-release formulation has been developed to improve adherence and possibly efficacy without compromising an excellent tolerability and safety profile. There is also a possibility of dose-dependent improvement/superiority in cognitive, global and behavioral measures as well as in verbal fluency with higher-dose (28 mg/day) memantine. WHAT THE READER WILL GAIN: Readers will become knowledgeable about this new dose and preparation of memantine. However, these advantages remain provisional and more research is needed to evaluate patient adherence, outcomes and caregiver burden related to twice-daily versus once-daily administration in patients with moderate to severe Alzheimer's disease. TAKE HOME MESSAGE: A new, once-daily, higher-dose preparation of memantine seems to be well tolerated and may provide additional benefits for selected patients with Alzheimer's disease.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Memantina/uso terapéutico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Preparaciones de Acción Retardada , Esquema de Medicación , Humanos , Memantina/administración & dosificación
12.
Clin Geriatr Med ; 26(2): 197-222, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20497841

RESUMEN

Increased longevity and population aging will increase the number of men with late-onset hypogonadism, a common condition that is often under diagnosed and under treated. The indication of testosterone replacement therapy (TRT) treatment requires the presence of low testosterone level and symptoms and signs of hypogonadism. Although there is a lack of large-scale, long-term studies assessing the benefits and risks of TRT in men with hypogonadism, reports indicate that TRT may produce a wide range of benefits that include improvement in libido and sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, cognition, quality of life, and cardiovascular disease. Perhaps the most controversial area is the issue of risk, especially the possible stimulation of prostate cancer by testosterone, even though there is no evidence to support this risk. Other possible risks include worsening symptoms of benign prostatic hypertrophy, liver toxicity, hyperviscosity, erythrocytosis, worsening untreated sleep apnea, or severe heart failure. Despite this controversy, testosterone supplementation in the United States has increased substantially in the past several years. The physician should discuss with the patient the potential benefits and risks of TRT. This review discusses the benefits and risks of TRT.


Asunto(s)
Envejecimiento/fisiología , Andrógenos/uso terapéutico , Terapia de Reemplazo de Hormonas , Hipogonadismo/tratamiento farmacológico , Testosterona/uso terapéutico , Edad de Inicio , Envejecimiento/efectos de los fármacos , Andrógenos/efectos adversos , Humanos , Hipogonadismo/diagnóstico , Masculino , Factores de Riesgo , Testosterona/efectos adversos , Testosterona/sangre , Testosterona/deficiencia , Resultado del Tratamiento
13.
Clin Geriatr Med ; 26(1): 57-74, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20176293

RESUMEN

There is a long history of hormones altering behavior and endocrinopathies playing a role in psychiatric disease. This article highlights the hormonal changes that occur with aging and the effects of these hormonal changes on the brain, concentrating not on the well-known psychiatric manifestations of endocrine diseases, but on the more subtle effects of hormones and metabolic alteration seen in many older persons. The article focuses predominately on the role of hormones in cognition, as dementia and mild cognitive impairment are major problems in the older individual.


Asunto(s)
Envejecimiento/fisiología , Envejecimiento/psicología , Encéfalo/fisiopatología , Trastornos del Conocimiento/etiología , Demencia/etiología , Enfermedades del Sistema Endocrino/psicología , Envejecimiento/patología , Encéfalo/metabolismo , Encéfalo/patología , Trastornos del Conocimiento/metabolismo , Trastornos del Conocimiento/prevención & control , Demencia/metabolismo , Demencia/prevención & control , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/terapia , Humanos
14.
Ther Clin Risk Manag ; 5(3): 427-48, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19707253

RESUMEN

Increased longevity and population aging will increase the number of men with late onset hypogonadism. It is a common condition, but often underdiagnosed and undertreated. The indication of testosterone-replacement therapy (TRT) treatment requires the presence of low testosterone level, and symptoms and signs of hypogonadism. Although controversy remains regarding indications for testosterone supplementation in aging men due to lack of large-scale, long-term studies assessing the benefits and risks of testosterone-replacement therapy in men, reports indicate that TRT may produce a wide range of benefits for men with hypogonadism that include improvement in libido and sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, cognition, quality of life and cardiovascular disease. Perhaps the most controversial area is the issue of risk, especially possible stimulation of prostate cancer by testosterone, even though no evidence to support this risk exists. Other possible risks include worsening symptoms of benign prostatic hypertrophy, liver toxicity, hyperviscosity, erythrocytosis, worsening untreated sleep apnea or severe heart failure. Despite this controversy, testosterone supplementation in the United States has increased substantially over the past several years. The physician should discuss with the patient the potential benefits and risks of TRT. The purpose of this review is to discuss what is known and not known regarding the benefits and risks of TRT.

15.
CNS Drugs ; 23(4): 293-307, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19374459

RESUMEN

The mainstay of current management of patients with Alzheimer's disease involves drugs that provide symptomatic therapy. Research approaches for future therapy of Alzheimer's disease are focusing on disease modifying and/or preventive approaches. Two classes of medications have been approved by the US FDA for the treatment of Alzheimer's disease: the cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine), mostly for mild to moderate Alzheimer's disease, and the noncompetitive NMDA receptor antagonist memantine for the moderate to severe stages of Alzheimer's disease. Management of comorbid medical problems can be more complex in patients with dementia than in those without dementia. Unfortunately, medication adherence in Alzheimer's disease is low and good adherence is essential for attempting to slow disease progression and improve or stabilize quality of life. Simplifying treatment regimens and providing more caregiver- and patient-friendly modes of administration that fit in better with daily routines can ease caregiver stress which, in turn, may have a favourable impact on the patient's condition. To overcome problems of medication adherence in the elderly, simple, user-friendly dosage regimens should be prescribed for all medications; thus the need for novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease, such as once-daily donepezil, memantine and galantamine, and transdermal rivastigmine.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Antipsicóticos/uso terapéutico , Protocolos Clínicos , Sistemas de Liberación de Medicamentos/métodos , Antipsicóticos/administración & dosificación , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA